IP Library › Granted Patent US 12,234,518
Granted Patent B2
US 12,234,518 · App. 17/507,697 · Granted Feb 25, 2025

Compositions and methods for analyzing DNA using partitioning and base conversion

Inventors: Andrew Kennedy (San Diego, CA); William J. Greenleaf (Menlo Park, CA)
Assignee: Guardant Health, Inc.
C12Q1/6886C12N9/22C12N15/1065C12N2800/80C12Q2600/112C12Q2600/154C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,518
App. No.
17/507,697
Granted
Feb 25, 2025
Kind
B2
Abstract

The present disclosure provides compositions and methods related to analyzing DNA, such as cell-free DNA. In some embodiments, the cell-free DNA is from a subject having or suspected of having cancer and/or the cell-free DNA includes DNA from cancer cells. In some embodiments, the DNA is partitioned into a first subsample and a second subsample, wherein the first subsample comprises DNA with a nucleotide modification (e.g., a cytosine modification) in a greater proportion than the second subsample, and the second subsample is subjected to a procedure that affects a first nucleobase in the DNA differently from a second nucleobase in the DNA of the first subsample, and the DNA is sequenced in a manner that distinguishes the first nucleobase from the second nucleobase in the DNA of the second subsample.

Claims (28)

1. A method of analyzing DNA in a sample, the method comprising:

a) partitioning the sample into a plurality of subsamples, including a first subsample and a second subsample, wherein the first subsample comprises DNA with a cytosine modification in a greater proportion than the second subsample;

b) subjecting the second subsample to a base conversion procedure that affects a first nucleobase in the DNA differently from a second nucleobase in the DNA of the second subsample, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first nucleobase and the second nucleobase have the same base pairing specificity, thereby producing a treated subsample;

c) capturing a target region set comprising epigenetic target regions from the treated subsample; and

d) sequencing DNA in the target region set and DNA from the first subsample, wherein DNA from the second subsample is sequenced in a manner that distinguishes the first nucleobase from the second nucleobase in the DNA of the target region set.

2. The method of claim 1 , wherein the target region set comprises a hypomethylation variable target region set.

3. The method of claim 2 , wherein the hypomethylation variable target region set comprises regions having a lower degree of methylation in at least one type of tissue than the degree of methylation in cell-free DNA from a healthy subject.

4. The method of claim 1 , wherein the target region set comprises a fragmentation variable target region set.

5. The method of claim 4 , wherein the fragmentation variable target region set comprises transcription start site regions and/or CTCF binding regions.

6. The method of claim 1 , wherein the target region set further comprises sequence-variable target regions.

7. The method of claim 6 , comprising sequencing DNA molecules corresponding to the sequence-variable target region set to a greater depth of sequencing than DNA molecules corresponding to the epigenetic target region set.

8. The method of claim 1 , wherein the DNA of the first subsample is contacted with a methylation-sensitive nuclease, thereby degrading nonspecifically partitioned DNA in the first subsample.

9. The method of claim 1 , wherein the DNA comprises cell-free DNA (cfDNA) obtained from a test subject.

10. The method of claim 1 , further comprising subjecting the first subsample to a procedure that affects a first nucleobase in the DNA differently from a second nucleobase in the DNA of the second subsample, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first nucleobase and the second nucleobase have the same base pairing specificity, thereby producing an additional treated subsample.

11. The method of claim 10 , further comprising capturing an additional target region set from the additional treated subsample, wherein the additional target region set comprises a hypermethylation variable target region set, a fragmentation variable target region set, and/or sequence-variable target regions.

12. The method of claim 11 , wherein the hypermethylation variable target region set comprises regions having a higher degree of methylation in at least one type of tissue than the degree of methylation in cell-free DNA from a healthy subject.

13. The method of claim 11 , wherein the fragmentation variable target region set comprises transcription start site regions and/or CTCF binding regions.

14. The method of claim 1 , wherein capturing comprises contacting DNA to be captured with a set of target-specific probes, whereby complexes of target-specific probes and DNA are formed.

15. The method of claim 1 , further comprising ligating barcode-containing adapters to the DNA before capture, optionally wherein the ligating occurs before or simultaneously with amplification.

16. The method of claim 1 , wherein partitioning the sample into a plurality of subsamples comprises partitioning on the basis of methylation level.

17. The method of claim 1 , comprising differentially tagging the first subsample and second subsample or the first subsample and the treated subsample.

18. The method of claim 17 , wherein DNA from the first subsample and the target region set or second subsample are pooled.

19. The method of claim 1 , wherein the plurality of subsamples comprises a third subsample, which comprises DNA with a cytosine modification in a greater proportion than the second subsample but in a lesser proportion than the first subsample.

20. The method of claim 19 , wherein the method further comprises differentially tagging DNA from the third subsample and DNA from the first subsample, and wherein DNA from the third sample and the target region set are pooled, optionally wherein DNA from the first, second, and third subsamples is sequenced in the same sequencing cell.

21. The method of claim 1 , further comprising determining a likelihood that the subject has cancer.

22. The method of claim 1 , wherein the first nucleobase is a modified or unmodified cytosine and the second nucleobase is a modified or unmodified cytosine.

23. The method of claim 22 , wherein the first nucleobase comprises unmodified cytosine (C) and the second nucleobase comprises 5-methylcytosine (mC) or 5-hydroxymethylcytosine (hmC).

24. The method of claim 23 , wherein the base conversion procedure to which the second subsample is subjected comprises Tet-assisted conversion with a substituted borane reducing agent, wherein the substituted borane reducing agent is 2-picoline borane, borane pyridine, tert-butylamine borane, or ammonia borane.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2021
From: KENNEDY, ANDREW; GREENLEAF, WILLIAM J.
To: GUARDANT HEALTH, INC.
Reel/Frame 058097/0529 →
Continuity (2)
Provisional Application 63105184 · Oct 23, 2020
Related Publication 20220154286A1 · May 19, 2022
References Cited (161)
US 5912148A · Eggerding · 1999 [cited by applicant]
US 6130073A · Eggerding · 2000 [cited by applicant]
US 6210891B1 · Nyren et al. · 2001 [cited by applicant]
US 6258568B1 · Nyren · 2001 [cited by applicant]
US 6582908B2 · Fodor et al. · 2003 [cited by applicant]
US 6833246B2 · Balasubramanian · 2004 [cited by applicant]
US 6969488B2 · Bridgham et al. · 2005 [cited by applicant]
US 7115400B1 · Adessi et al. · 2006 [cited by applicant]
US 7169560B2 · Lapidus et al. · 2007 [cited by applicant]
US 7170050B2 · Turner et al. · 2007 [cited by applicant]
US 7282337B1 · Harris · 2007 [cited by applicant]
US 7302146B2 · Turner et al. · 2007 [cited by applicant]
US 7313308B2 · Turner et al. · 2007 [cited by applicant]
US 7329492B2 · Hardin et al. · 2008 [cited by applicant]
US 7476503B2 · Turner et al. · 2009 [cited by applicant]
US 7482120B2 · Buzby · 2009 [cited by applicant]
US 7501245B2 · Quake et al. · 2009 [cited by applicant]
US 7537898B2 · Bost et al. · 2009 [cited by applicant]
US 8486630B2 · Pan et al. · 2013 [cited by applicant]
US 9074013B2 · Rehli · 2015 [cited by applicant]
US 9598731B2 · Talasaz · 2017 [cited by applicant]
US 9611510B2 · He et al. · 2017 [cited by applicant]
US 9738894B2 · Elmen et al. · 2017 [cited by applicant]
US 9850523B1 · Chudova et al. · 2017 [cited by applicant]
US 9902992B2 · Talasaz et al. · 2018 [cited by applicant]
US 10612088B2 · Shishkin et al. · 2020 [cited by applicant]
US 20010053519A1 · Fodor et al. · 2001 [cited by applicant]
US 20030152490A1 · Trulson et al. · 2003 [cited by applicant]
US 20090208941A1 · Berlin et al. · 2009 [cited by applicant]
US 20100105049A1 · Ehrich et al. · 2010 [cited by applicant]
US 20110160078A1 · Fodor et al. · 2011 [cited by applicant]
US 20110237444A1 · Clancy et al. · 2011 [cited by applicant]
US 20120208193A1 · Okino et al. · 2012 [cited by applicant]
US 20130143211A1 · Ehrich et al. · 2013 [cited by applicant]
US 20130157266A1 · Hanna et al. · 2013 [cited by applicant]
US 20130244885A1 · Wang et al. · 2013 [cited by applicant]
US 20140322707A1 · He et al. · 2014 [cited by applicant]
US 20140363815A1 · Dahl et al. · 2014 [cited by applicant]
US 20150044687A1 · Schmitt et al. · 2015 [cited by applicant]
US 20150299812A1 · Talasaz · 2015 [cited by applicant]
US 20150368708A1 · Talasaz · 2015 [cited by applicant]
US 20160040229A1 · Talasaz et al. · 2016 [cited by applicant]
US 20160046986A1 · Eltoukhy et al. · 2016 [cited by applicant]
US 20160047001A1 · Larisch et al. · 2016 [cited by applicant]
US 20160108476A1 · Schweiger et al. · 2016 [cited by applicant]
US 20160201142A1 · Lo et al. · 2016 [cited by applicant]
US 20170211143A1 · Shendure et al. · 2017 [cited by applicant]
US 20180120304A1 · Rao et al. · 2018 [cited by applicant]
US 20180251848A1 · Diehn et al. · 2018 [cited by applicant]
US 20180305738A1 · Kennedy et al. · 2018 [cited by applicant]
US 20190144848A1 · Carvalho et al. · 2019 [cited by applicant]
US 20190390253A1 · Kennedy et al. · 2019 [cited by applicant]
US 20200248272A1 · Kennedy et al. · 2020 [cited by applicant]
US 20210115502A1 · Mortimer et al. · 2021 [cited by applicant]
US 20220162670A1 · Kennedy et al. · 2022 [cited by applicant]
EP 1693468A1 · 2006 [cited by applicant]
EP 2805769A1 · 2014 [cited by applicant]
WO 2015061359A1 · 2015 [cited by applicant]
WO 2015159292A2 · 2015 [cited by applicant]
WO 2016015058A2 · 2016 [cited by applicant]
WO 2016115530A1 · 2016 [cited by applicant]
WO 2017181146A1 · 2017 [cited by applicant]
WO 2017181161A1 · 2017 [cited by applicant]
WO 2017184707A1 · 2017 [cited by applicant]
WO 2017190215A1 · 2017 [cited by applicant]
WO 2018005811A1 · 2018 [cited by applicant]
WO 2018009723A1 · 2018 [cited by applicant]
WO 2018119452A2 · 2018 [cited by applicant]
WO 2019010564A1 · 2019 [cited by applicant]
WO WO2019136413A4 · 2019 [cited by examiner]
WO 2020006369A1 · 2020 [cited by applicant]
WO 2020160414A1 · 2020 [cited by applicant]
Nair, S. et al. “Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cells” Chem Commun (2015) 51(15):3266-3269. [cited by applicant]
Nair, S.S. et al. “Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias” Epigenetics (2011) … [cited by applicant]
Newman, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. May 2014;20(5):548-54. doi: 10.1038/nm.3519. Epub Apr. 6, 2014. [cited by applicant]
Niazi, U. et al. “DISMISS: detection of stranded methylation in MeDIP-Seq data” BMC Bioinformatics (2016) 17:295 12 pages. [cited by applicant]
Ning, Z. et al. “SSAHA: A Fast Search Method for Large DNA Databases” Genome Res (2001) 11:1725-1729. [cited by applicant]
Ooki, A. et al. “A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA” (2017) Clin. Cancer Res. 23:7141-7152. [cited by applicant]
Palmisano, W. et al. “Aberrant Promoter Methylation of the Transcription Factor Genes PAX5 alpha and beta in Human Cancers” Cancer Res (2003) 63:4620-4625. [cited by applicant]
Paweletz, C.P. et al. “Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients” Clin Canc Res (2016) 22(4):915-92… [cited by applicant]
Pearson, W.R. et al. “Improved tools for biological sequence comparison” PNAS (1988) 85:2444-2448. [cited by applicant]
Phallen, J. et al. “Direct detection of early-stage cancers using circulating tumor DNA” Sci Trans Med (2017) vol. 9, Issue 403, eaan2415DOI: 10.1126/scitranslmed.aan2415. [cited by applicant]
Reuter, J.A. et al. “Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling”, Nature Methods (Oct. 10, 2016) 13(11):953-958. [cited by applicant]
Rhee, H.S. et al. “Comprehensive genome-wide protein-DNA interactions detected at single-nucleotide resolution” Cell (2011) 147:1408-1419. [cited by applicant]
Riebler, A. et al. “BayMeth: improved DNA methylation quantification for affinity capture sequencing data using a flexible Bayesian approach” Genome Biology (2014) 15:R35 19 pages. [cited by applicant]
Robinson, M.D. et al. “Evaluation of affinity-based genome-wide DNA methylation data: Effects of CpG density, amplification bias, and copy number variation” Genome Research (2010) 20(12):1719-1729. [cited by applicant]
Rohland, N. et al. “Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture” Genome Res (2012) 22(5):939-946. [cited by applicant]
Schneider, K.U. et al. “Correlation of SHOX2 Gene Amplification and DNA Methylation in Lung Cancer Tumors” BMC Cancer (2011) 11:102. [cited by applicant]
Schutsky, E.K. et al., “Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase” Nature Biotech (2018); 36:1083-1090. [cited by applicant]
Severin, P.M.D. et al. “Cytosine methylation alters DNA mechanical properties” Nucl Acids Res (2011) 39:8740-8751. [cited by applicant]
Shen, S.Y. et al. “Sensitive tumour detection and classification using plasma cell-free DNA methylomes” Nature (2018) 563(7732):579-583. [cited by applicant]
Shi, Y-X et al. “Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer” BMC Genomics (2017) 18:901. [cited by applicant]
Skvortsova, T.E. et al. “Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation” Br J Cancer (2006) 94(10):1492-1495. [cited by applicant]
Smallwood, S.A. et al. “Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity” Nature Methods (2014) 11(8):817-820. [cited by applicant]
Snyder, M.W. et al. “Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin” Cell (2016) 164:57-68 & Supplemental Information. [cited by applicant]
Song, C-X. et al. “Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine” Nature Biotech (2011) 29:68-72. [cited by applicant]
Stirzaker, C. et al. “Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value” Nature Comm (2015) 6(5899) (15 pages). [cited by applicant]
Sun, Q et al. “N6-methyladenine functions as a potential epigenetic mark in eukaryotes” Bioessays (2015) 37:1155-1162. [cited by applicant]
Suzuki, H. et al. “Genome-wide Profiling of Chromatin Signatures Reveals Epigenetic Regulation of MicroRNA Genes In Colorectal Cancer” Cancer Research (2011) 71(17):5646-5658. [cited by applicant]
Thakur, B.K. et al. “Double-stranded DNA in exosomes: a novel biomarker in cancer detection” Cell Research—Xibao Yanjiu (Apr. 8, 2014) 24(6):766-769. [cited by applicant]
Toyooka, K.O. et al. “Loss of Expression and Aberrant Methylation of the CDH13 (H-Cadherin) Gene in Breast and Lung Carcinomas” Cancer Res. (2001) 61:4556-4560. [cited by applicant]
Vaisvila, R. et al. “EM-seq: Detection of DNA Methylation at Single Base Resolution from Picograms of DNA” bioRxiv (2019) DOI:10.1101/2019.12.20.884692. [cited by applicant]
Voelkerding, K.V. et al. “Next-generation sequencing: from basic research to diagnostics” Clin Chem (2009) 55:641-658. [cited by applicant]
Warton, K. et al. “Methylation of cell-free circulating DNA in the diagnosis of cancer” Frontiers in Mol Biosciences (2015) 2(13), 10 pages. [cited by applicant]
Warton, K. et al. “Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma” BMC Genomics (2014) 15:476 13 pages. [cited by applicant]
Wielscher, M. et al. “Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing” BMC Clin Path (2011) 11:11 (9 pages). [cited by applicant]
Yamashita, R. et al. “DBTSS: DataBase of Human Transcription Start Sites, progress report 2006” Nucleic Acids Res. (2006) 34(Database issue): D86-D89. [cited by applicant]
Yigit, E. et al. “Genome and metagenome sequencing: Using the human methyl-binding domain to partition genomic DNA derived from plant tissues” Appl Plant Sci (2014) 2(11):1400064. [cited by applicant]
Yu, M. et al. “Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome” Cell (2012) 149 (6):1368-1380. [cited by applicant]
Zhao, Y. et al. “Methylcap-Seq Reveals Novel DNA Methylation Markers for the Diagnosis and Recurrence Prediction of Bladder Cancer in a Chinese Population” PLoS One 7(4):e35175 (12 pages), 2012. [cited by applicant]
International search report & written opinion for International Application No. PCT/US2021/056106 dated Mar. 2, 2022. [cited by applicant]
Astier, Y. et al. “Toward Single Molecule DNA Sequencing: Direct Identification of Ribonucleoside and Deoxyribonucleoside 5′-Monophosphates by Using an Engineered Protein Nanopore Equipped with a Molecular Adapter” J Am… [cited by applicant]
Belinsky, S.A. “Unmasking the lung cancer epigenome” Annu. Rev. Physiol. (2015) 77:453-474. [cited by applicant]
Bock, C. et al. “Quantitative comparison of genome-wide DNA methylation mapping technologies” Nature Biotech (2010) 28:1106-1114. [cited by applicant]
Booth, M.J. et al. “Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution” Science (2012) 336(6083):934-937. [cited by applicant]
Burnham, P. et al. “Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma” Sci Reports (Jun. 14, 2016) 6(1), XP055472868, DOI: 10.1038/srep27859. [cited by applicant]
Clark, T.A. et al. “Analytical Validation of a Hybrid Capture Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA,” J. Mol. Diagnostics (2018) 20(5):686-702. [cited by applicant]
Cock, PJA, et al. “The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants” NAR (2009) 38(6):1767-1771. [cited by applicant]
Cuddapah, S. et al. “Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains” Genome Res (2009) 19:24-32. [cited by applicant]
Danecek, P. et al. “The variant call format and VCFtools” Bioinformatics (2011) 27(15):2156-2158. [cited by applicant]
Dey, S.S. et al. “Integrated genome and transcriptome sequencing of the same cell” Nature Biotech (Jan. 19, 2015) 33 (3):285-589. [cited by applicant]
Ehrlich, M. “DNA hypomethylation in cancer cells” Epigenomics 1:239-259, 2019. [cited by applicant]
Fisher et al., “Characterization of cytosine methylated regions and 5-cytosine DNA methyltransferase (Ehmeth) in the protozoan parasite Entamoeba histolytica,” Nucleic Acids Research, 2004, vol. 32, No. 1, pp. 287-297. [cited by applicant]
Freier, S.M. et al. “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes” Nucl Acids Res (1997) 25:4429-4443. [cited by applicant]
Furonaka, O. et al. “Aberrant methylation and loss of expression of O6-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma” Pathol Int (2005) 55:303-309. [cited by applicant]
Gale, D. et al. “Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA” PLoS One (2018) 13:e0194630. [cited by applicant]
Gansauge, M-T. et al. “Single-stranded DNA library preparation for the sequencing of ancient or damaged DNA” Nature Protocols (2013) 3:737-748. [cited by applicant]
Gomes, A. et al. “Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung” Rev. Port. Pneumol. (2014) 20:20-30. [cited by applicant]
Greer, E.L. et al. “DNA Methylation on N6-Adenine in C. elegans” Cell (2015) 161(4):868-878. [cited by applicant]
Guo, M. et al. “Hypermethylation of the GATA genes in lung cancer” Clin Cancer Res (2004) 10(23):7917-7924. [cited by applicant]
Guo, Y.A. et al. “Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers” Nature Commun (2018) 9:1520. [cited by applicant]
Han, D. et al. “A highly sensitive and robust method for genome-wide 5hmC profiling of rare cell populations” Mol Cell. (2016) 63(4):711-719. [cited by applicant]
Heller, G. et al. “Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas” Oncogene (2006) 25:959-968. [cited by applicant]
Hon, G.C. et al. “Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer” Genome Res (2012) 22:246-258. [cited by applicant]
Hopkins-Donaldson, S. et al. “Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation” Cell Death Differ. (2003) 10:356-64. [cited by applicant]
Hulbert, A. et al. “Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum” Clin. Cancer Res. (2017) 23:1998-2005. [cited by applicant]
International search report and written opinion dated Dec. 15, 2020 for PCT/US2020/053610. [cited by applicant]
Iurlaro, M. et al. “A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation” Genome Biology (2013) 14:R119. [cited by applicant]
Jeong, H.M. et al. “Efficiency of methylated DNA immunoprecipitation bisulphite sequencing for whole-genome DNA methylation analysis” Epigenomics (2016) 8(8):1061-1077. [cited by applicant]
Jin, H. et al. “Circulating Methylated DNA as Biomarkers for Cancer Detection” Methylation: From DNA, RNA and Histones to Diseases and Treatment (2012) InTech. XP055479454, DOI:10.5772./51419. [cited by applicant]
Kang, S. et al. “CancerLocator: non-invasive cancer diagnosis and tissue-of origin prediction using methylation profiles of cell-free DNA” Genome Biology (2017) 18(1):53 XP055682390. [cited by applicant]
Katainen, R. et al. “CTCF/cohesin-binding sites are frequently mutated in cancer” Nature Genetics (2015) 47:818-821. [cited by applicant]
Kikuchi, S. et al. “Promoter Methylation of DAL-1/4.1B Predicts Poor Prognosis in Non Small Cell Lung Cancer” Clin Canc Res (2005) 11:2954-2961. [cited by applicant]
Kim et al., “Whole genome MBD-seq and RRBS analyses reveal that hypermethylation of gastrointestinal hormone receptors is associated with gastric carcinogenesis,” Experimental & Molecular Medicine (2018) 50:156 (14 page… [cited by applicant]
Kim, D-H. et al. “p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer” Canc Res (2001) 61:3419-3424. [cited by applicant]
Kim, D-H. et al. “Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer” Oncogene. (2001) 20:1765-1770. [cited by applicant]
Kinde, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. Jun. 7, 2011;108(23):9530-5. doi: 10.1073/pnas.1105422108. Epub May 17, 2011. [cited by applicant]
Kinde, et al. Supplemental Information, Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. Jun. 7, 2011;108(23):1-10. [cited by applicant]
Kou, R. et al. “Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations” PLoS One (2016) 11: e0146638, https://doi.org/10.1371/journal.pone.0146… [cited by applicant]
Kumar, S. et al. “Epigenetics of Modified DNA Bases: 5-Methylcytosine and Beyond” Frontiers Genet (2018) 9:640. [cited by applicant]
Lam, K. et al. “DNA methylation based biomarkers in colorectal cancer: A systematic review” Biochim Biophys Acta (2016 ) 1866(1):106-20. [cited by applicant]
Levy, S.E. et al. “Advancements in Next-Generation Sequencing” Ann Rev Genomics & Hum Genetics (2016) 17:95-115. [cited by applicant]
Li et al., “Combining MeDIP-seq and MRE-seq to investigate genome-wide CpG methylation,” Methods. Jan. 15, 2015; 72: 29-40 (28 pages). [cited by applicant]
Li, et al., The Sequence Alignment/Map format and SAMtools, Bioinformatics, 2009, 25(16):2078-9. [cited by applicant]
Licchesi, J. et al. “Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung” Carcinogenesis (2008) 29:895-904. [cited by applicant]
Lissa, D. et al. “Methylation analyses in liquid biopsy” Transl Lung Cancer Res (2016) 5(5):492-504. [cited by applicant]
Liu, L. et al. “Comparison of Next-Generation Sequencing Systems” J Biomed & Biotech (2012) Article ID251364:1-11. [cited by applicant]
Liu, Y. et al. “Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution” Nature Biotech (2019) 37(4):424-429. [cited by applicant]
MacLean, D. et al. “Application of ‘next-generation’ sequencing technologies to microbial genetics” Nature Rev Microbiol (2009) 7:287-296. [cited by applicant]
Martin, D. et al. “Genome-wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes” Nature Structural Mol Bio (2011) 18:708-714. [cited by applicant]
Moss, J. et al. “Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease” Nat Comm (2018) 9:5068. [cited by applicant]